leuprorelin Vials, injection 3.75mg, 7.5 mg, 30 mg

Leuprorelin

Leuprorelin, also called Leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty. It is also indicated in the treatment of estrogen-dependent conditions such as endometriosis or uterine fibroids. It may be used to prevent premature ovulation in cycles of controlled ovarian stimulation for IVF amongst teens with precocious puberty in both males and females. In combination with other drugs, it delays puberty in transgender youth until they are old enough for hormone replacement therapy. Leuprorelin is sold under the brand name Lupron among others. Bayer AG markets Leuprorelin under the brand name Viadur. It is also marketed by Tolmar under the brand names Eligard and Fensolvi and by TAP Pharmaceuticals and Abbott as Lupron. It was first patented in 1973, and approved for sales in the United States in 1985. It is on the World Health Organization's List of Essential Medicines. Leuprorelin use is off-label, for not having the approval of the Food and Drug Administration and without data on long- term effects of this use. In Europe, In the UK and Ireland, Takeda UK, as Prostap SR and Prostap 3, markets it.

Forms and Dosage

Leuprorelin is sold as a slow-release implant or subcutaneous/intramuscular injection. It is sold as Short-acting daily intramuscular injection or as a Long-acting depot intramuscular injection or as a Long-acting depot subcutaneous injection or Long-acting subcutaneous injection or a Long-acting subcutaneous implant. In the treatment of Advanced Prostate Cancer, a standard dose is 7.5 mg IM monthly or 22.5 mg IM every 3 months or 30 mg IM every 4 months, or 45 mg IM every 6 months. In the treatment of Endometriosis, the dose is 3.75 mg IM monthly for up to 6 months or 11.25 mg IM every 3 months for 2 doses for a total of 6 months.

How does it work?

Leuprorelin is a gonadotropin-releasing hormone analogue that acts as an agonist at pituitary GnRH receptors. Initially, Agonism of GnRH receptors results in the stimulation of luteinizing hormone and follicle-stimulating hormone secretion by the anterior pituitary eventually leading to increased serum estradiol and testosterone levels via the normal physiology of the hypothalamic–pituitary–gonadal axis. But, Pituitary GnRH receptors become de-sensitised after weeks of continuous therapy. This protracted down-regulation of GnRH receptor activity is the key objective of Leuprorelin therapy and ultimately results in decreased LH and FSH secretion, leading to Hypogonadism and thus a dramatic reduction in estradiol and testosterone levels regardless of sex. while treating prostate cancer, the initial increase in testosterone levels can be associated with Leuprorelin therapy is counterproductive to treatment goals.

Finding Leuprorelin Manufacturers and Suppliers

The process of finding trusted Leuprorelin manufacturers and Leuprorelin suppliers can be made simpler, quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is an easy to use online platform to grow your business opportunities. The robust search engine makes it convenient to search for manufacturers and suppliers of Leuprorelin. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily.